Original articleMacular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials
Section snippets
Study Population
Details of the design and methods for CATT have been published.1, 2, 3 A total of 1185 subjects were enrolled by 43 clinical centers in the United States between February 2008 and December 2009. Only 1 eye per subject, the study eye, was treated as a part of the clinical trial. Inclusion criteria included age ≥50 years, presence of previously untreated active CNV secondary to age-related macular degeneration (AMD) in the study eye, and VA between 20/25 and 20/320. Choroidal neovascularization
Optical Coherence Tomography Morphologic Characteristics Over Time by Treatment Group
After anti-VEGF therapy, in all treatment groups there was a similar proportion of eyes with fluid of any type (IRF, SRF, or sub-RPE) from week 52 to week 104, except for the ranibizumab switched group, which showed an increase in the relative proportion of participants with fluid of any type (Fig 1A). The majority of this increase in the proportion of participants with fluid of any type in the ranibizumab switched group occurred between weeks 52 and 76. There was relatively little change
Discussion
During year 2 of this study, the week 52 associations of morphologic features determined on OCT, FA, and FP and VA were maintained or strengthened at week 104. In contrast to the large decreases in year 1 of the study, anti-VEGF treatment did not further reduce macular fluid, thickness, or vascular leakage, or stabilize lesion growth. Despite a lack of additional year 2 improvement in morphologic features, anti-VEGF therapy maintained or improved the VA gains achieved in year 1 of the study for
References (11)
- et al.
Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials
Ophthalmology
(2013) - et al.
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results
Ophthalmology
(2012) - et al.
Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials
Ophthalmology
(2012) - et al.
Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials
Ophthalmology
(2012) - et al.
Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration
Ophthalmology
(2015)
Cited by (175)
Non-neovascular fluid in age-related macular degeneration: observe-and-extend regimen in a case-series study
2023, Canadian Journal of OphthalmologyResponse of extra-large pigment epithelial detachment to intravitreal brolucizumab injection
2023, American Journal of Ophthalmology Case ReportsPseudophakia as a surprising protective factor in neovascular age-related macular degeneration
2023, Journal Francais d'OphtalmologieAge-related macular degeneration
2023, The LancetLong-term effect of fluid volumes during the maintenance phase in neovascular age-related macular degeneration: results from Fight Retinal Blindness!
2023, Canadian Journal of OphthalmologyPreliminary study on the efficacy of subretinal injection of Aflibercept in the treatment of refractory polypoidal choroidal vasculopathy
2024, Chinese Journal of Ocular Fundus Diseases
∗Supplemental material is available at www.aaojournal.org.
Financial Disclosure(s): The author(s) have made the following disclosure(s): C.A.T.: Grants − Duke from the National Eye Institute, during the conduct of the study; Grants − Genentech, Bioptigen; Personal fees − Thrombogenics, outside the submitted work; Patent − OCT technology and software (pending).
M.G.M.: Personal fees − Genentech.
G.-S.Y.: Personal fees − Janssen R & D.
G.J.J.: Personal fees − Heidelberg Engineering, Neurotech, Alcon/Novartis, Genentech/Roche.
Supported by cooperative agreements U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828, and R21EY023689 from the National Eye Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland. The funding organization participated in the design and conduct of the study and review of the manuscript. ClinicalTrials.gov identifier NCT00593450.
Author Contributions:
Conception and design: Sharma, Toth, Daniel, Grunwald, Maguire, Ying, Huang, Martin, Jaffe
Data collection: Sharma, Toth, Daniel, Grunwald, Maguire, Ying, Huang, Martin, Jaffe
Analysis and interpretation: Sharma, Toth, Daniel, Grunwald, Maguire, Ying, Huang, Martin, Jaffe
Obtained funding: Not applicable
Overall responsibility: Sharma, Toth, Daniel, Grunwald, Maguire, Ying, Huang, Martin, Jaffe
- ∗
A list of group members for the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group appears in the Appendix (available at www.aaojournal.org).